OTCs and arthritis
This article was originally published in The Tan Sheet
Executive Summary
Recent NSAID publicity has affected the way 82% of orthopedic surgeons recommend pain relievers, according to the results of a telephone survey by Florida Hospital and the Joint Replacement Center released Aug. 10. The survey, which polled 259 specialists between June 16 and July 7, reports that 70% of orthopedic surgeons prescribe OTC medication for minor arthritis pain rather than Rx drugs. Of the group, 58% prefer Aleve, 35% recommend Advil and 7% suggest Tylenol as the first line of treatment against arthritis pain. Aleve ranked No. 1 for its "easy dosing" with "fewer pills" and long-lasting relief. The survey measured how surgeons are reacting to new NSAID data and reports that 90% of orthopedic surgeons have decreased prescribing COX-2 inhibitors in favor of OTCs...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.